Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20420898 | 0.90 | CACNA1G (0.48) | CACNA1GCACNA1HCACNA1IMEN1KMT2A | |
| SCHEMBL17078837 | 0.88 | LMNA (0.49) | ALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL17078707 | 0.88 | DPP4 (0.48) | CACNA1GCACNA1HCACNA1ISMN1; SMN2MAPT | |
| SCHEMBL20432638 | 0.87 | HDAC6 (0.58) | MEN1KMT2APOLB | |
| SCHEMBL17078604 | 0.87 | HDAC6 (0.58) | MEN1KMT2APOLB | |
| SCHEMBL17078965 | 0.85 | GRIN2B (0.57) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17078739 | 0.85 | MEN1 (0.48) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL18701038 | 0.84 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17078801 | 0.84 | OPRD1 (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL17086785 | 0.83 | HDAC1 (0.58) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | disclosed |
| EP-3116859-B1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-08-01 | — | — | EP | disclosed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | disclosed |
| EP-3116859-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015137750-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | HDAC6, HDAC1, HDAC11 | CA1 661/4885CA2 1790/4885CACNA1G 2884/4885 |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC6, HDAC1, HDAC5 | CA1 437/4885CA2 1695/4885CACNA1G 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.